Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.

TitleBrain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease.
Publication TypeJournal Article
Year of Publication2002
AuthorsDeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM
JournalScience
Volume295
Issue5563
Pagination2264-7
Date Published2002 Mar 22
ISSN1095-9203
KeywordsAlzheimer Disease, Amino Acid Substitution, Amyloid beta-Peptides, Amyloidosis, Animals, Antibodies, Monoclonal, Brain, Cerebral Cortex, Disease Models, Animal, Hippocampus, Humans, Mice, Protein Transport, Solubility, Time Factors
Abstract

The deposition of amyloid-beta (Abeta) peptides into amyloid plaques precedes the cognitive dysfunction of Alzheimer's disease (AD) by years. Biomarkers indicative of brain amyloid burden could be useful for identifying individuals at high risk for developing AD. As in AD in humans, baseline plasma Abeta levels in a transgenic mouse model of AD did not correlate with brain amyloid burden. However, after peripheral administration of a monoclonal antibody to Abeta (m266), we observed a rapid increase in plasma Abeta and the magnitude of this increase was highly correlated with amyloid burden in the hippocampus and cortex. This method may be useful for quantifying brain amyloid burden in patients at risk for or those who have been diagnosed with AD.

DOI10.1126/science.1067568
Alternate JournalScience
PubMed ID11910111
Grant ListAG20222 / AG / NIA NIH HHS / United States